The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Cost-effective osteoporosis treatment thresholds: the United States perspective
Open accessAbstract
Unlabelled A United States-specific cost-effectiveness analysis, which incorporated the cost and health consequences of clinical fractures of the hip, spine, forearm, shoulder, rib, pelvis and lower leg, was undertaken to identify the 10-year hip fracture probability required for osteoporosis treatment to be cost-effective for cohorts defined by age, sex, and race/ethnicity. A 3% 10-year risk of hip fracture was generally required for osteoporosis treatment to cost less than $60,000 per QALY gained. Introduction Rapid growth of the elderly United States population will result in so many at risk of osteoporosis that economically efficient approaches to osteoporosis care warrant consideration. Methods A Markov-cohort model of annual United States age-specific incidence of clinical hip, spine, forearm, shoulder, rib, pelvis and lower leg fractures, costs (2005 US dollars), and quality-adjusted life years (QALYs) was used to assess the cost-effectiveness of osteoporosis treatment ($600/yr drug cost for 5 years with 35% fracture reduction) by gender and race/ethnicity groups. To determine the 10-year hip fracture probability at which treatment became cost-effective, average annual age-specific probabilities for all fractures were multiplied by a relative risk (RR) that was systematically varied from 0 to 10 until a cost of $60,000 per QALY gained was observed for treatment relative to no intervention. Results Osteoporosis treatment was cost-effective when the 10-year hip fracture…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The latter analyses generally confirm the previous NOF conclusion that it is cost-effective to treat individuals with a prior hip or vertebral fracture and those with a DXA femoral neck T-score ≤−2.5.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [12]
In the citing paper
“The latter analyses generally confirm the previous NOF conclusion that it is cost-effective to treat individuals with a prior hip or vertebral fracture and those with a DXA femoral neck T-score ≤−2.5.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [12]
In the citing paper
“Therapeutic intervention thresholds are based on NOF’s economic analysis that takes into consideration the cost-effectiveness of treatments and competition for resources in the USA [12, 13].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [12]
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Self-citationEpidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821 · cited 2×
“Although osteoporotic fractures are less common among non-white populations and men [14], it was assumed that, should a fracture occur, the associated reduction in quality of life would be the same as for a postmenopausal white woman.”
BackgroundMethodSelf-citationMarkov Models in Medical Decision Making: A Practical Guide
Sonnenberg, F. A., & Beck, J. R. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300409 · Cited by 2,419
A meta-analysis of previous fracture and subsequent fracture risk
Kanis, J. A., Johnell, O., De Laet, C., Johansson, H., Oden, A., Delmas, P., Eisman, J., Fujiwara, S., Garnero, P., Kroger, H., et al. (2004) · Bone · doi:10.1016/j.bone.2004.03.024 · Cited by 1,278
Self-citationKanis, J. A., Borgstrom, F., De Laet, C., Johansson, H., Johnell, O., Jonsson, B., Oden, A., Zethraeus, N., Pfleger, B., & Khaltaev, N. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1780-5 · Cited by 1,233
Population-Based Study of Survival after Osteoporotic Fractures
Cooper, C., Atkinson, E. J., Jacobsen, S. J., O’Fallon, W. M., & Melton, L. J. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116756 · Cited by 1,100
Self-citationMortality and morbidity after hip fractures.
Keene, G. S., Parker, M. J., & Pryor, G. A. (1993) · BMJ · doi:10.1136/bmj.307.6914.1248 · Cited by 876
The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds
Kanis, J. A., Oden, A., Johnell, O., Jonsson, B., de Laet, C., & Dawson, A. (2001) · Osteoporosis International · doi:10.1007/s001980170112 · Cited by 726
II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women
Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Adachi, J., Shea, B., Tugwell, P., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-2002 · Cited by 445
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Self-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
“Several studies have examined the costeffectiveness of intervention thresholds expressed in terms of fracture probability [123, 127, 130, 360, 361].”
BackgroundPapaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Metadata
- Authors
- Tosteson, A. N. A., Melton, L. J., Dawson-Hughes, B., Baim, S., Favus, M. J., Khosla, S., & Lindsay, R. L.
- Affiliations
- Dartmouth Institute for Health Policy and Clinical Practice (US)
- Mayo Clinic (US)
- Medical College of Wisconsin (US)
- University of Chicago (US)
- Helen Hayes Hospital (US)
- Corresponding author
- Tosteson, A. N. A.
- Venue
- Osteoporosis International
- Published
- 2008-02-22
- Volume
- 19
- Issue
- 4
- Pages
- 437-447
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC2729707
- OpenAlex
- W2144832496
- Cited by
- 441
- References
- 38
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 8 · 2023: 16 · 2022: 15 · 2021: 20 · 2020: 18 · 2019: 19 · 2018: 21 · 2017: 14 · 2016: 21 · 2015: 26 · 2014: 21 · 2013: 29 · 2012: 40
- FWCI
- 49.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p60ar048094-05)
- National Institute on Aging (AG12262, R01AG012262)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR048094, P60-AR048094)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis treatment, cost-effectiveness, hip fracture, fracture risk prediction, quality-adjusted life years, sex differences, racial and ethnic differences, older adults, treatment thresholds
- MeSH terms
- Age Factors, Aged, Aged, 80 and over, Algorithms, Cost-Benefit Analysis, Female, Humans, Male, Middle Aged, Osteoporosis, Probability, Time Factors, United States, Health Care Costs, Models, Economic, Quality-Adjusted Life Years, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effective osteoporosis treatment thresholds: the United States perspective. https://app.cochat.ai/papers/10.1007/s00198-007-0550-6
- The paper
- Tosteson, A. N. A., Melton, L. J., Dawson-Hughes, B., Baim, S., Favus, M. J., Khosla, S., & Lindsay, R. L. (2008). Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporosis International. https://doi.org/10.1007/s00198-007-0550-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.